584 related articles for article (PubMed ID: 15870412)
1. 20-year outcomes following conservative management of clinically localized prostate cancer.
Albertsen PC; Hanley JA; Fine J
JAMA; 2005 May; 293(17):2095-101. PubMed ID: 15870412
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival among men with conservatively treated localized prostate cancer.
Albertsen PC; Fryback DG; Storer BE; Kolon TF; Fine J
JAMA; 1995 Aug 23-30; 274(8):626-31. PubMed ID: 7637143
[TBL] [Abstract][Full Text] [Related]
3. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.
Albertsen PC; Hanley JA; Gleason DF; Barry MJ
JAMA; 1998 Sep; 280(11):975-80. PubMed ID: 9749479
[TBL] [Abstract][Full Text] [Related]
4. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
D'Amico AV; Renshaw AA; Sussman B; Chen MH
JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
[TBL] [Abstract][Full Text] [Related]
6. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
Albertsen PC; Hanley JA; Penson DF; Barrows G; Fine J
J Urol; 2007 Mar; 177(3):932-6. PubMed ID: 17296379
[TBL] [Abstract][Full Text] [Related]
7. Natural history of early, localized prostate cancer: a final report from three decades of follow-up.
Popiolek M; Rider JR; Andrén O; Andersson SO; Holmberg L; Adami HO; Johansson JE
Eur Urol; 2013 Mar; 63(3):428-35. PubMed ID: 23084329
[TBL] [Abstract][Full Text] [Related]
8. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
9. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Lin Y; DiPaola RS; Yao SL
Eur Urol; 2015 Nov; 68(5):805-11. PubMed ID: 25800944
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer and the Will Rogers phenomenon.
Albertsen PC; Hanley JA; Barrows GH; Penson DF; Kowalczyk PD; Sanders MM; Fine J
J Natl Cancer Inst; 2005 Sep; 97(17):1248-53. PubMed ID: 16145045
[TBL] [Abstract][Full Text] [Related]
11. Natural history of early, localized prostate cancer.
Johansson JE; Andrén O; Andersson SO; Dickman PW; Holmberg L; Magnuson A; Adami HO
JAMA; 2004 Jun; 291(22):2713-9. PubMed ID: 15187052
[TBL] [Abstract][Full Text] [Related]
12. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
13. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
14. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study.
Hoffman RM; Barry MJ; Stanford JL; Hamilton AS; Hunt WC; Collins MM
Am J Med; 2006 May; 119(5):418-25. PubMed ID: 16651054
[TBL] [Abstract][Full Text] [Related]
15. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.
Graff JN; Mori M; Li H; Garzotto M; Penson D; Potosky AL; Beer TM
J Urol; 2007 Apr; 177(4):1307-12. PubMed ID: 17382720
[TBL] [Abstract][Full Text] [Related]
16. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
[TBL] [Abstract][Full Text] [Related]
17. PSA and the conservative treatment of early prostate cancer.
Albertsen PC
Arch Ital Urol Androl; 2006 Dec; 78(4):152-3. PubMed ID: 17269621
[TBL] [Abstract][Full Text] [Related]
18. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of localized prostate cancer following conservative management.
Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Barry MJ; Zietman A; O'Leary M; Walker-Corkery E; Yao SL
JAMA; 2009 Sep; 302(11):1202-9. PubMed ID: 19755699
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]